Cancer Hospital Cancer Institute
Cancer Hospital Cancer Institute
Cao A.-Y.,Breast Cancer Institute |
Cao A.-Y.,Fudan University |
Huang L.,Breast Cancer Institute |
Huang L.,Fudan University |
And 13 more authors.
World Journal of Surgical Oncology | Year: 2012
Background: We sought to compare the baseline demographics, standard pathologic factors and long-term clinical outcomes between ILC and infiltrating ductal carcinoma (IDC) using a large database.Methods: Clinicopathologic features, overall survival (OS), and recurrence/metastasis-free survival (RFS) were compared between 2,202 patients with IDC and 215 patients with ILC.Results: ILC was significantly more likely to be associated with a favorable phenotype, but the incidence of contralateral breast cancer was higher for ILC patients than for IDC patients (8.4% vs. 3.9%; P =0.001). The frequencies of recurrence/metastasis (P = 0.980) and death (P = 0.064) were similar among patients with IDC and patients with ILC after adjustment for tumor size and nodal status. The median follow-up was 42.8 months.Conclusions: Chinese women with ILCs do not have better clinical outcomes than their counterparts with IDC. Management decisions should be based on individual patient and tumor biologic characteristics, and not on lobular histology. © 2012 Cao et al.; licensee BioMed Central Ltd.
Liu X.-F.,Nanjing Medical University |
Liu X.-F.,Cancer Hospital Cancer Institute |
Li L.-F.,Cancer Hospital Cancer Institute |
Li L.-F.,Henan Province Tumor Hospital |
And 3 more authors.
BMC Cancer | Year: 2012
Background: Different ethnicities have different distribution of Duffy blood group (DBG) phenotypes and different breast cancer morbidity. A study in our lab demonstrated that Duffy antigen/receptor for chemokines (DARC, also known as DBGP, the Duffy protein phenotype), led to the inhibition of tumorigenesis. Therefore, we tested the hypothesis that DBGP is correlated with breast cancer occurrence.Methods: DBGP proteins were examined by indirect antiglobulin testing with anti-FYa and anti-FYb antibodies. The phenotypes were classified into four groups according to the agglutination reactions: FYa + FYb+, FYa + FYb-, FYa-FYb + and FYa-FYb- The phenotypes and pathological diagnosis of consecutively hospitalized female patients (n = 5,022) suffering from breast cancer at the Shanghai Cancer Hospital and Henan Province Cancer Hospital were investigated. The relationships between DBGP expression with breast cancer occurrence, axillary lymph status, histological subtype, tumor size pathological grade and overall survival were analyzed.Results: The incidence of breast cancer was significantly different between FYa + FYb + (29.8%), FYa + FYb- (33.2%), FYa-FYb + (45.6%) and FYa-FYb- (59.1%; P = 0.001). Significant different numbers of breast cancer patients had metastases to the axillary lymph nodes in the FYa + FYb + group (25.1%), FYa + FYb- (36.9%), FYa-FYb + (41.0%) and FYa-FYb- (50.0%, (P = 0.005). There was a statistical significance (p = 0.022) of the overall survival difference between patients with difference phenotypes. No significant difference was observed in cancer size (t-test, p > 0.05), histological cancer type (Fisher's exact test, p > 0.05) or histological grade (Fisher's exact test, p > 0.05) between every each DBGP group.Conclusions: DBGP is correlated with breast cancer incidence and axillary lymph node metastasis and overall survival. Further investigations are required to determine the underlying mechanism of Duffy blood group phenotype on breast cancer risk. © 2012 Liu et al.; licensee BioMed Central Ltd.
PubMed | Cancer Hospital Cancer Institute
Type: Journal Article | Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2016
9653 Background:To evaluate the prognostic value of HER2/neu over-expression in node-negative patients.Specimens from the primary tumors of 137 axillary lymph node negative patients who underwent surgery between 1990-1998 were obtained from the files of the Department of Pathology at Cancer Hospital,Fudan University following an approved institutional review board protocol. Immunohistochemical analysis of HER2/neu protein expression in breast carcinoma samples was performed. We analyze the association of HER2/neu over-expression with other clinic-pathological factors by chi-square test. Univariate and multivariate analysis were performed to evaluate the prognostic significance of HER2/neu over-expression in relapse free survival and overall survival.We found HER2/neu over-expression had no correlation with other clinic-pathological factors such as menopausal status, tumor size, tumor grade, p53, ER and histotype. We also found over-expression of HER2/neu is a significantly unfavorable prognostic factor for RFS in steroid receptor positive patients(log-rank test, p=0.0011), but not ER and PR negative patients. Multivariate analysis showed that HER2/neu together with tumor size and p53 was independently prognostic factor for RFS in node-negative patients (p<0.05).We concluded that for lymph node-negative patients, HER2/neu over-expression combined with steroid receptor status can be meaningful to patientsprognosis. No significant financial relationships to disclose.